Teva is starting Phase III trials for a long-acting injectable formulation of olanzapine, partner MedinCell has revealed. The move comes after the pair were knocked back on their partnered risperidone product earlier this year by the US FDA, with a new expected launch date for that product now also disclosed by the French company.
Teva has moved ahead with the start of Phase III trials for the mdc-TJK long-acting injectable olanzapine candidate which it has co-developed with its partner, Montpellier-based MedinCell.
The move comes after the partners were knocked back by the US Food and Drug Administration earlier this year for...